AMA Assigns PLA CPT Code 0640U to Plus Therapeutics’ CNSide CSF Tumor Cell Test

Overview

• Plus Therapeutics, which announced Tuesday that the AMA assigned PLA CPT code 0640U to its CNSide cerebrospinal fluid tumor‑cell test, said the code takes effect July 1, 2026.
• PLA codes are AMA-issued CPT entries for single‑laboratory tests that give each assay a distinct billing identifier used in claims and payer review.
• The new code creates a clear claims pathway that can cut paperwork for oncologists and neurologists evaluating patients for leptomeningeal metastases.
• The identifier enables national tracking through insurance claims, letting the company build real‑world evidence on clinical outcomes and health‑care costs.
• Shares of Plus Therapeutics fell about 4.8% Tuesday after the update, and the next steps center on payer coverage decisions and broader clinical uptake during the U.S. launch.